Pilot Projects Investigating Understudied Proteins Associated with Rare Diseases (R03 Clinical Trial Not Allowed)
Can you apply?
This grant is for researchers and research institutions investigating understudied proteins associated with rare diseases. Eligible applicants typically include academic medical centers, research universities, independent research institutes, and other research organizations that hold or can obtain an active NIH institutional grant (PHS 5161 or equivalent). Applicants must have appropriate laboratory facilities and institutional review board (IRB) or other appropriate oversight. The program supports exploratory and developmental research through pilot projects, with the intent to generate preliminary data that will lead to larger, future grant applications. Clinical trials are not permitted for this mechanism.
This grant is for researchers and research institutions investigating understudied proteins associated with rare diseases. Eligible applicants typically include academic medical centers, research universities, independent research institutes, and other research organizations that hold or can obtain an active NIH institutional grant (PHS 5161 or equivalent). Applicants must have appropriate laboratory facilities and institutional review board (IRB) or other appropriate oversight. The program supports exploratory and developmental research through pilot projects, with the intent to generate preliminary data that will lead to larger, future grant applications. Clinical trials are not permitted for this mechanism.
Program description
The purpose of this notice of funding opportunity (NOFO) is to solicit applications for pilot projects to elucidate a role for understudied proteins in rare disease. Awards will support generation of preliminary data and/or tools around eligible understudied protein(s). A list of eligible proteins is provided and are members of druggable protein families that have a known association with a rare disease. This NOFO is intended to jumpstart research on understudied proteins that are associated with rare diseases and provide applicants with sufficient funding to perform basic biochemical and/or biological work to further the characterization of understudied proteins within the context of rare disease.
Who can apply
Eligible applicants
- 501(c)(3) Public Charity
- City / Municipal Government
- County Government
- Nonprofits
- Private University
- Public Authority
- Public K-12 School
- Public University
- Small Business (SBA-defined)
- Special District
- State Government
- Tribal Nation
- Tribal Organization
Details
This grant is for researchers and research institutions investigating understudied proteins associated with rare diseases. Eligible applicants typically include academic medical centers, research universities, independent research institutes, and other research organizations that hold or can obtain an active NIH institutional grant (PHS 5161 or equivalent). Applicants must have appropriate laboratory facilities and institutional review board (IRB) or other appropriate oversight. The program supports exploratory and developmental research through pilot projects, with the intent to generate preliminary data that will lead to larger, future grant applications. Clinical trials are not permitted for this mechanism.
How to apply
Application links
Required documents
- NIH Form SF-424 (R&R)
- Project Narrative (research strategy section typically 6-12 pages)
- Biographical Sketch for all senior/key personnel
- Budget and Budget Justification (detailed line-item budget required)
- Institutional Review Board (IRB) approval letter or evidence of exemption (if human subjects involved)
- Institutional Commitment and Assurances
- Current and Pending Support documentation
- Letters of support (if collaborators involved)
- Environment and Facilities documentation
Program contact
- 👤 National Institutes of Health
- 📧 grantsinfo@nih.gov
- 📞 301-402-2541
Funding track record
Recent awards under CFDA 93.121 from the last 3 years — real organizations that won funding through this same program.
Top 10 Largest Recent Awards
-
$443,702,768
-
$32,310,944
-
$31,252,186
-
$29,535,192
-
$23,987,187
-
$23,513,241
-
$18,362,716
-
$16,829,492
-
$15,691,075
-
$14,460,130
Top States by Funding
- WA 2 awards $451.4M
- CA 13 awards $134.6M
- MI 4 awards $75.8M
- PA 4 awards $67.6M
- MA 5 awards $39.0M
Source: USAspending.gov — federal spending transparency. Data covers last 3 years.
Funding history
Annual funding for this program — Federal obligations (CFDA 93.121). How funding has trended year over year.
| 2024 | $319,987,302 | |
| 2025 | $332,151,837 | |
| 2026 est. | $337,316,521 |
FAQ
Who is eligible to apply for this grant?
Researchers at research institutions including universities, medical schools, research institutes, and hospitals are eligible. Individual researchers must be affiliated with an eligible institution. Both early-career and established investigators may apply.
What types of projects are supported?
This mechanism supports exploratory and developmental research focused on understudied proteins involved in rare disease mechanisms. Projects should generate preliminary data to support future larger grant applications. Clinical trials are not permitted.
What is the typical funding range?
R03 grants typically provide up to $150,000-$300,000 total costs over 2 years, though amounts can vary. Check the specific funding opportunity announcement for exact limits.
What is the application deadline?
The deadline for this cycle is November 16, 2027. However, NIH typically has multiple submission dates per year, so check NIH Grants.gov for additional deadlines.
What makes a competitive application?
Strong applications clearly define the understudied proteins being investigated, demonstrate feasibility with preliminary data, articulate how results will advance knowledge of rare disease mechanisms, and have a realistic budget and timeline for a 2-year pilot project.
💡 Tips for applicants
- Start with a focused research question about specific understudied proteins; avoid overly broad protein families or too many simultaneous targets
- Include preliminary data showing feasibility of your approach, even if limited—this is critical for R03 success
- Clearly explain why these particular proteins are understudied and why your investigation matters for rare disease understanding
- Budget conservatively; reviewers expect well-justified costs appropriate to a 2-year pilot, not a full-scale research program
- Build a strong case for how your pilot data will enable a future larger grant application (R01, R21, etc.), showing the pathway to continued funding
⚠️ Common mistakes
Applications are often rejected when they lack preliminary data or proof-of-concept, propose overly ambitious scope for a 2-year pilot mechanism, or fail to clearly justify why the selected proteins are truly understudied and relevant to rare disease pathophysiology. Weak applications also sometimes omit a clear vision for how the pilot project will lead to larger future grants.
Similar grants
- OPEN 27-0343-10 FFY27 Local Agency General Non-Enforcement — Illinois Department of Transportation
- ROLLING Annual Agency Threshold Application Applicants for Funding Start Here — Texas City of Austin - Austin Public Health
- CLOSED Virginia’s Black Indigenous and People of Color (BIPOC) Grant – FY26 — Virginia The Virginia Department of Historic Resources
- ROLLING RTAP Grant Program (Rolling) — Virginia Department of Rail and Public Transportation
- ROLLING Rail Industrial Access Grant (RIA) — Virginia Department of Rail and Public Transportation